Rapport Therapeutics (RAPP) Competitors $13.97 -0.84 (-5.67%) As of 01/13/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RAPP vs. KYMR, EWTX, DYN, ARWR, CPRX, AMRX, NAMS, LBPH, IOVA, and PTGXShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Kymera Therapeutics (KYMR), Edgewise Therapeutics (EWTX), Dyne Therapeutics (DYN), Arrowhead Pharmaceuticals (ARWR), Catalyst Pharmaceuticals (CPRX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Longboard Pharmaceuticals (LBPH), Iovance Biotherapeutics (IOVA), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Kymera Therapeutics Edgewise Therapeutics Dyne Therapeutics Arrowhead Pharmaceuticals Catalyst Pharmaceuticals Amneal Pharmaceuticals NewAmsterdam Pharma Longboard Pharmaceuticals Iovance Biotherapeutics Protagonist Therapeutics Rapport Therapeutics (NASDAQ:RAPP) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings, dividends and community ranking. Does the media favor RAPP or KYMR? In the previous week, Rapport Therapeutics and Rapport Therapeutics both had 10 articles in the media. Rapport Therapeutics' average media sentiment score of 0.99 beat Kymera Therapeutics' score of 0.88 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, RAPP or KYMR? Rapport Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$34.79MN/AN/AKymera Therapeutics$87.56M27.29-$146.96M-$2.34-15.77 Does the MarketBeat Community believe in RAPP or KYMR? Kymera Therapeutics received 52 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Rapport Therapeutics an outperform vote while only 52.94% of users gave Kymera Therapeutics an outperform vote. CompanyUnderperformOutperformRapport TherapeuticsOutperform Votes2100.00% Underperform VotesNo VotesKymera TherapeuticsOutperform Votes5452.94% Underperform Votes4847.06% Do analysts prefer RAPP or KYMR? Rapport Therapeutics currently has a consensus target price of $35.00, suggesting a potential upside of 150.54%. Kymera Therapeutics has a consensus target price of $55.38, suggesting a potential upside of 50.07%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Rapport Therapeutics is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Kymera Therapeutics 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88 Is RAPP or KYMR more profitable? Rapport Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -191.26%. Rapport Therapeutics' return on equity of 0.00% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A N/A N/A Kymera Therapeutics -191.26%-24.96%-20.27% SummaryRapport Therapeutics beats Kymera Therapeutics on 8 of the 12 factors compared between the two stocks. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$510.97M$6.66B$5.31B$8.82BDividend YieldN/A2.91%5.07%4.00%P/E RatioN/A10.1585.8216.79Price / SalesN/A188.641,103.51115.75Price / CashN/A57.6843.2137.77Price / BookN/A4.975.104.88Net Income-$34.79M$153.46M$122.01M$228.12M7 Day Performance-21.43%-6.42%-3.65%-3.81%1 Month Performance-25.57%-1.41%0.27%0.01%1 Year PerformanceN/A-3.38%25.26%13.15% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics2.1982 of 5 stars$13.97-5.7%$35.00+150.5%N/A$510.97MN/A0.00N/ANews CoverageGap DownKYMRKymera Therapeutics2.6208 of 5 stars$39.90-4.1%$55.38+38.8%+32.4%$2.58B$87.56M-17.05170EWTXEdgewise Therapeutics2.0223 of 5 stars$26.56-4.2%$43.17+62.5%+153.3%$2.51BN/A-17.7160Short Interest ↑Gap DownDYNDyne Therapeutics3.3597 of 5 stars$24.57-0.8%$49.91+103.1%-8.4%$2.50BN/A-6.90100ARWRArrowhead Pharmaceuticals4.2275 of 5 stars$19.50-1.5%$43.33+122.2%-48.1%$2.43B$3.55M-3.88400Positive NewsCPRXCatalyst Pharmaceuticals4.6672 of 5 stars$20.19-5.3%$31.14+54.2%+53.3%$2.41B$460.48M17.11167Analyst DowngradeShort Interest ↑AMRXAmneal Pharmaceuticals3.9514 of 5 stars$7.77-0.6%$10.00+28.7%+43.0%$2.41B$2.68B-11.437,700Short Interest ↓NAMSNewAmsterdam Pharma2.5337 of 5 stars$25.85-0.3%$38.17+47.6%+40.2%$2.39B$33.59M0.0057Analyst ForecastLBPHLongboard Pharmaceuticals0.2278 of 5 stars$59.98+0.0%$63.00+5.0%+155.8%$2.34BN/A-26.9020IOVAIovance Biotherapeutics4.1358 of 5 stars$7.48-2.2%$23.00+207.5%-35.8%$2.28B$90.86M-5.02500PTGXProtagonist Therapeutics2.8516 of 5 stars$38.09-3.7%$53.78+41.2%+43.4%$2.27B$323.80M14.32125 Related Companies and Tools Related Companies KYMR Competitors EWTX Competitors DYN Competitors ARWR Competitors CPRX Competitors AMRX Competitors NAMS Competitors LBPH Competitors IOVA Competitors PTGX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RAPP) was last updated on 1/14/2025 by MarketBeat.com Staff From Our Partners$24 trillion tech spotted at Mar-a-Lago?President Trump’s Secret Service was recently spotted using an odd new technology at his home in Mar-a-Lago…Centurion Publishing | SponsoredCharles Payne Wants You Prepared for 2025Charles Payne Wants You Prepared for 2025 There's no denying that market volatility, inflation, and recessi...Unstoppable Prosperity | SponsoredGreatest crypto bull market in history?A crypto storm is coming Right now, conditions are in place for a historic move we expect will be the great...Stansberry Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
